Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Moderna (MRNA) has reiterated its target of up to 10% revenue growth in 2026, supported by a strategy to build a large ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Moderna said it expects 2025 revenue of approximately $1.9 billion, which is $100 million above the midpoint previously ...

Market Domination Overtime Host Josh Lipton tracks several of the day's top trending stock tickers, including Adobe's stock ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are ...

US biotech Moderna today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 ...